Wow, just saw uniQure's stock got absolutely wrecked today - down 42% to $9.10. Turns out the FDA basically rejected their AMT-130 gene therapy data from Phase I/II trials for Huntington's disease. They're saying the external control comparison isn't enough and want a full randomized, double-blind, sham-controlled Phase III study instead. That's... a pretty big setback. The company's CEO says they'll keep working with FDA on this, but yeah, that's a lot of ground to make up. Gene therapy is risky business apparently. Anyone following this stock?

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin